Citi resumed coverage of Medline (MDLN) with a Buy rating and $60 price target following a period of suspension. The company’s Q4 report came in well ahead of expectations on broad-based strength, the analyst tells investors in a research note. Citi believes Medline has a “compelling set-up” into fiscal 2026 as a “safety trade.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLN:
- Medline price target raised to $53 from $50 at JPMorgan
- Medline price target raised to $60 from $55 at Tigress Financial
- Medline 75M share Secondary priced at $41.00
- Medline announces launch of secondary offering of Class A common stock
- Medline files to sell 75M shares of Class A common stock for holders